Sinocare

Sinocare EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Sinocare (300298.SZ) as of Oct 20, 2026 is 23.56. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 20.27 — a change of 16.23% (higher).

EV/FCF

23.56

YoY

16.23%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Sinocare is 2025 23.56 . EV/FCF (Enterprise Value to Free Cash Flow) of Sinocare was 2024 20.27 . It decreases by 16.23% higher compared to the previous year.

The Sinocare EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
113.32 CNY
Jan 1, 2019
88.92 CNY
Jan 1, 2020
38.35 CNY
Jan 1, 2021
119.29 CNY
Jan 1, 2022
55.47 CNY
Jan 1, 2023
24.55 CNY
Jan 1, 2024
20.27 CNY
Jan 1, 2025
23.56 CNY
The Sinocare EV/FCF history
YEAREV/FCFYoY
23.56+16.23%
20.27-17.41%
24.55-55.74%
55.47-53.50%
119.29+211.04%
38.35-56.87%
88.92-21.53%
113.32+81.55%
62.42+0.86%
61.89-56.95%
143.76+37.70%
104.40—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sinocare Stock analysis

What does Sinocare do? Sinocare, Inc. generates revenue through the development, production, and sale of chronic disease rapid detection products, primarily focusing on blood sugar monitoring systems. The company offers blood sugar testing instruments, related strips, blood sugar testing systems, and mobile blood sugar instruments under its SANNUO brand. These products are sold domestically and internationally, targeting healthcare providers and consumers managing diabetes. Sinocare also provides diabetes management information systems as part of its product portfolio. The SANNUO brand is central to Sinocare's sales strategy, with products distributed across domestic and overseas markets. The company's offerings include micro blood instant blood sugar monitoring systems, which are designed for chronic disease management. Sinocare's revenue streams are derived from direct sales of these medical devices and associated information systems to end-users and healthcare institutions. Sinocare's business model relies on the consistent demand for diabetes management solutions, with its SANNUO-branded products serving both individual consumers and healthcare facilities. The company's product range includes blood sugar testing instruments, strips, and mobile blood sugar instruments, all marketed under the SANNUO label. These products are distributed globally, supporting Sinocare's revenue generation through direct sales channels. Sinocare is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sinocare stock

EV/FCF (Enterprise Value to Free Cash Flow) of Sinocare is 23.56 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Sinocare changed from 20.27 to 23.56, representing a 16.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Sinocare since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Sinocare with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Sinocare

All Key Metrics — Sinocare